| Environmental Protection: | Yes |
|---|---|
| Color: | White |
| Appearance: | Powder |
| CAS No.: | 2381089-83-2 |
| MOQ: | 1g |
| Stock Condition: | in Stock |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
|
Product Name
|
Retatrutide |
|
Cas
|
2381089-83-2 |
|
Analysis
|
HPLC
|
|
Storage
|
Keep in a cool and dry place, well-closed, away from moisture or direct sunlight.
|
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist of GLP-1, GIP, and GCGR receptors.[1] It has been shown to achieve a more than 24% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial
Our company has established a US warehouse. Once consumers place an order, they can receive the goods within 48 hours without high shipping costs.
| Semaglutide | Vial package | 5mg 10mg 15mg |
| Tirzepatide | Vial package | 5mg 10mg 15mg |
| Retatrutide | Vial package | 5mg 10mg 15mg |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}